Brooklyn ImmunoTherapeutics Inc. [AMEX: BTX] surged by $0.92 during the normal trading session on Monday and reaching a high of $17.45 during the day while it closed the day at $15.22. The company report on June 14, 2021 that Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics.
Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologies.
Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announced it has executed a non-binding letter of intent (“LOI”) to acquire Novellus Therapeutics (“Novellus”), a company developing next-generation engineered mesenchymal stem cell (“MSC”) therapies using patented mRNA cell reprogramming and gene editing technologies licensed from Factor Bioscience (“Factor”). It is expected that the transaction will involve an acquisition by Brooklyn of all of the outstanding equity of Novellus (the “Transaction”).
Brooklyn ImmunoTherapeutics Inc. stock has also gained 1.26% of its value over the past 7 days. However, BTX stock has inclined by 101.86% in the 3 months of the year. Over the past six months meanwhile, it has gained 257.28% and gained 239.73% year-on date.
The market cap for BTX stock reached $670.14 million, with 27.80 million shares outstanding and 19.05 million shares in the current float. Compared to the average trading volume of 7.49M shares, BTX reached a trading volume of 6916758 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Brooklyn ImmunoTherapeutics Inc. [BTX]:
The Average True Range (ATR) for Brooklyn ImmunoTherapeutics Inc. is set at 3.83, with the Price to Sales ratio for BTX stock in the period of the last 12 months amounting to 197.10.
BTX stock trade performance evaluation
Brooklyn ImmunoTherapeutics Inc. [BTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.26. With this latest performance, BTX shares dropped by -35.04% in over the last four-week period, additionally plugging by 257.28% over the last 6 months – not to mention a rise of 604.63% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BTX stock in for the last two-week period is set at 44.89, with the RSI for the last a single of trading hit 43.08, and the three-weeks RSI is set at 47.26 for Brooklyn ImmunoTherapeutics Inc. [BTX]. The present Moving Average for the last 50 days of trading for this stock 19.97, while it was recorded at 14.95 for the last single week of trading.
Brooklyn ImmunoTherapeutics Inc. [BTX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Brooklyn ImmunoTherapeutics Inc. [BTX] shares currently have an operating margin of -93.09 and a Gross Margin at +46.41. Brooklyn ImmunoTherapeutics Inc.’s Net Margin is presently recorded at -76.12.
Return on Total Capital for BTX is now -76.52, given the latest momentum, and Return on Invested Capital for the company is -94.09. Return on Equity for this stock declined to -148.60, with Return on Assets sitting at -45.35. When it comes to the capital structure of this company, Brooklyn ImmunoTherapeutics Inc. [BTX] has a Total Debt to Total Equity ratio set at 245.59. Additionally, BTX Total Debt to Total Capital is recorded at 71.06, with Total Debt to Total Assets ending up at 49.83. Long-Term Debt to Equity for the company is recorded at 62.59, with the Long-Term Debt to Total Capital now at 18.09.
Reflecting on the efficiency of the workforce at the company, Brooklyn ImmunoTherapeutics Inc. [BTX] managed to generate an average of -$200,682 per employee. Receivables Turnover for the company is 8.85 with a Total Asset Turnover recorded at a value of 0.60.Brooklyn ImmunoTherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.20.
Brooklyn ImmunoTherapeutics Inc. [BTX]: Insider Ownership positions
There are presently around $2 million, or 0.40% of BTX stock, in the hands of institutional investors. The top three institutional holders of BTX stocks are: EAGLE ASSET MANAGEMENT INC with ownership of 46,826, which is approximately 33.172% of the company’s market cap and around 7.80% of the total institutional ownership; CITADEL ADVISORS LLC, holding 22,849 shares of the stock with an approximate value of $0.35 million in BTX stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.3 million in BTX stock with ownership of nearly New of the company’s market capitalization.
Positions in Brooklyn ImmunoTherapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 8 institutional holders increased their position in Brooklyn ImmunoTherapeutics Inc. [AMEX:BTX] by around 83,047 shares. Additionally, 5 investors decreased positions by around 8,214 shares, while 3 investors held positions by with 58,082 shares. The mentioned changes placed institutional holdings at 149,343 shares, according to the latest SEC report filing. BTX stock had 5 new institutional investments in for a total of 55,650 shares, while 2 institutional investors sold positions of 8,124 shares during the same period.